KALA BIO, INC. (KALA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseKALA / S&P -80.00% / 15.20% |
LoseKALA / S&P KALA unavailable / 15.00% |
LoseKALA / S&P -86.42% / 50.40% |
| 2026-Q10/3 |
LoseKALA / S&P -68.88% / -4.33% |
LoseKALA / S&P KALA unavailable / 11.30% |
LoseKALA / S&P 11.60% / 27.70% |
| 2025-Q41/3 |
LoseKALA / S&P -63.66% / 2.65% |
LoseKALA / S&P KALA unavailable / 9.00% |
WinKALA / S&P 1352.97% / 13.40% |
| 2025-Q31/3 |
LoseKALA / S&P -67.86% / 8.12% |
LoseKALA / S&P KALA unavailable / 4.61% |
WinKALA / S&P 1192.10% / 13.45% |
| 2025-Q21/3 |
LoseKALA / S&P -16.93% / 10.94% |
LoseKALA / S&P KALA unavailable / 4.83% |
WinKALA / S&P 1059.37% / 10.63% |
| 2025-Q11/3 |
LoseKALA / S&P -17.44% / -4.27% |
LoseKALA / S&P KALA unavailable / 4.98% |
WinKALA / S&P 415.04% / 10.57% |
| 2024-Q41/3 |
WinKALA / S&P 21.75% / 2.41% |
LoseKALA / S&P KALA unavailable / 5.25% |
LoseKALA / S&P -39.38% / 6.15% |
| 2024-Q30/3 |
LoseKALA / S&P -19.61% / 5.89% |
LoseKALA / S&P KALA unavailable / 5.89% |
LoseKALA / S&P -46.09% / 6.11% |
| 2024-Q21/3 |
LoseKALA / S&P -11.04% / 4.28% |
LoseKALA / S&P KALA unavailable / 5.38% |
WinKALA / S&P 11366.67% / 5.12% |
| 2024-Q11/3 |
WinKALA / S&P 13.86% / 10.56% |
LoseKALA / S&P KALA unavailable / 5.71% |
LoseKALA / S&P 1.91% / 5.59% |
| 2023-Q40/3 |
LoseKALA / S&P -21.35% / 11.69% |
LoseKALA / S&P KALA unavailable / 6.81% |
LoseKALA / S&P -40.58% / 7.78% |
| 2023-Q30/3 |
LoseKALA / S&P -39.00% / -3.27% |
LoseKALA / S&P KALA unavailable / 7.52% |
LoseKALA / S&P -59.59% / -5.03% |
| 2023-Q20/3 |
LoseKALA / S&P -3.06% / 8.74% |
LoseKALA / S&P KALA unavailable / 9.50% |
LoseKALA / S&P -99.88% / -8.57% |
| 2023-Q10/3 |
LoseKALA / S&P -60.55% / 7.50% |
LoseKALA / S&P KALA unavailable / 10.77% |
LoseKALA / S&P -81.34% / -15.69% |
| 2022-Q41/3 |
WinKALA / S&P 245.25% / 7.56% |
LoseKALA / S&P -65.37% / 11.88% |
LoseKALA / S&P -47.59% / -17.99% |
| 2022-Q30/3 |
LoseKALA / S&P -26.33% / -4.88% |
LoseKALA / S&P -50.54% / 13.47% |
LoseKALA / S&P KALA unavailable / -1.41% |
| 2022-Q20/3 |
LoseKALA / S&P -78.26% / -16.10% |
LoseKALA / S&P -22.09% / 13.71% |
LoseKALA / S&P KALA unavailable / 11.04% |
| 2022-Q11/3 |
WinKALA / S&P 14.05% / -4.60% |
LoseKALA / S&P 9.22% / 15.97% |
LoseKALA / S&P KALA unavailable / 42.23% |
| 2021-Q41/3 |
LoseKALA / S&P -53.82% / 11.03% |
WinKALA / S&P 76.67% / 15.00% |
LoseKALA / S&P KALA unavailable / 96.40% |
| 2021-Q31/3 |
LoseKALA / S&P -50.57% / 0.58% |
WinKALA / S&P 119.12% / 10.77% |
LoseKALA / S&P KALA unavailable / 69.42% |
| 2021-Q21/3 |
LoseKALA / S&P -21.36% / 8.55% |
WinKALA / S&P 137.60% / 6.58% |
LoseKALA / S&P KALA unavailable / 51.81% |
| 2021-Q11/3 |
LoseKALA / S&P -0.59% / 6.17% |
WinKALA / S&P 48.58% / -1.06% |
LoseKALA / S&P KALA unavailable / 7.39% |
| 2020-Q41/3 |
LoseKALA / S&P -9.60% / 12.15% |
WinKALA / S&P 4.74% / -3.72% |
LoseKALA / S&P KALA unavailable / -33.42% |
| 2020-Q30/3 |
LoseKALA / S&P -28.64% / 8.93% |
LoseKALA / S&P KALA unavailable / -2.04% |
LoseKALA / S&P KALA unavailable / -27.10% |
| 2020-Q20/3 |
LoseKALA / S&P 19.57% / 20.54% |
LoseKALA / S&P KALA unavailable / -0.46% |
LoseKALA / S&P KALA unavailable / -27.11% |
| 2020-Q11/3 |
WinKALA / S&P 138.21% / -19.60% |
LoseKALA / S&P KALA unavailable / 3.47% |
LoseKALA / S&P KALA unavailable / -14.75% |
| 2019-Q40/3 |
LoseKALA / S&P -3.02% / 9.07% |
LoseKALA / S&P KALA unavailable / 5.36% |
LoseKALA / S&P KALA unavailable / 2.99% |
| 2019-Q30/3 |
LoseKALA / S&P -40.36% / 1.70% |
LoseKALA / S&P KALA unavailable / 5.02% |
LoseKALA / S&P KALA unavailable / 0.21% |
| 2019-Q20/3 |
LoseKALA / S&P -22.85% / 4.30% |
LoseKALA / S&P KALA unavailable / 6.64% |
LoseKALA / S&P KALA unavailable / 8.65% |
| 2019-Q11/3 |
WinKALA / S&P 69.12% / 13.65% |
LoseKALA / S&P KALA unavailable / 8.12% |
LoseKALA / S&P KALA unavailable / 14.29% |
| 2018-Q40/3 |
LoseKALA / S&P -50.46% / -13.52% |
LoseKALA / S&P KALA unavailable / 9.05% |
LoseKALA / S&P KALA unavailable / 18.23% |
| 2018-Q30/3 |
LoseKALA / S&P -28.11% / 7.71% |
LoseKALA / S&P KALA unavailable / 10.21% |
LoseKALA / S&P KALA unavailable / 19.06% |
| 2018-Q20/3 |
LoseKALA / S&P -13.27% / 3.43% |
LoseKALA / S&P KALA unavailable / 9.03% |
LoseKALA / S&P KALA unavailable / 14.46% |
| 2018-Q10/3 |
LoseKALA / S&P -14.39% / -0.76% |
LoseKALA / S&P KALA unavailable / 7.68% |
LoseKALA / S&P KALA unavailable / 12.46% |
| 2017-Q40/3 |
LoseKALA / S&P -19.05% / 6.64% |
LoseKALA / S&P KALA unavailable / 7.03% |
LoseKALA / S&P KALA unavailable / 13.82% |
| 2017-Q30/3 |
LoseKALA / S&P KALA unavailable / 4.48% |
LoseKALA / S&P KALA unavailable / 5.68% |
LoseKALA / S&P KALA unavailable / 17.57% |
| 2017-Q20/3 |
LoseKALA / S&P KALA unavailable / 3.09% |
LoseKALA / S&P KALA unavailable / 4.83% |
LoseKALA / S&P KALA unavailable / 17.74% |
| 2017-Q10/3 |
LoseKALA / S&P KALA unavailable / 6.07% |
LoseKALA / S&P KALA unavailable / 3.67% |
LoseKALA / S&P KALA unavailable / 13.32% |
| 2016-Q40/3 |
LoseKALA / S&P KALA unavailable / 3.82% |
LoseKALA / S&P KALA unavailable / 2.09% |
LoseKALA / S&P KALA unavailable / 7.05% |
| 2016-Q30/3 |
LoseKALA / S&P KALA unavailable / 3.85% |
LoseKALA / S&P KALA unavailable / 0.20% |
LoseKALA / S&P KALA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | KALA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.86% | 20.78% |
| Annualized return | -99.86% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | KALA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.99% | 83.14% |
| Annualized return | -84.40% | 12.86% |
10Y · 2017-07-20 to 2026-08-27
| Metric | KALA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -66.54% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |